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Abstract
Background: Diabetes mellitus is a risk factor for tuberculosis (TB) disease. There is evidence that diabetes also influences TB
severity and treatment outcomes but information is incomplete and some published results have been inconsistent.
Methods: A longitudinal cohort study was conducted at the National Masan Tuberculosis Hospital in the Republic of Korea.
Subjects presenting with a first episode of TB or for retreatment of TB were followed from enrollment through completion
of treatment. Demographic, clinical, and microbiological variables were recorded, along with assessment of outcomes.
Results were compared in TB patients with and without diabetes or smoking history. Data were adjusted for gender, age,
cohort, educational level and alcohol consumption.
Results: The combined cohorts comprised 657 subjects. Diabetes was present in 25% and was associated with greater
radiographic severity and with recurrent or relapsed TB. Diabetes and cigarette smoking independently increased the risk of
death in the first 12 months after enrollment. Estimating the combined impact of diabetes and smoking yielded a hazard
ratio of 5.78. Only 20% of diabetic subjects were non-smokers; 54% smoked $1 pack daily. In this cohort, the impact of
diabetes on mortality was greater in patients younger than 50 years, compared to older patients.
Conclusions: In this cohort of Korean patients, diabetes exacerbated the severity of TB disease. Diabetic subjects who
smoked$1 pack of cigarettes daily were at particularly high risk of death from TB. Strategies to improve TB outcomes could
productively focus resources for patient education and TB prevention on the vulnerable population of younger diabetics,
particularly those who also smoke.
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Introduction
Tuberculosis (TB) remains a major cause of morbidity and
mortality from infectious disease worldwide [1]. It is estimated that
two billion people are presently infected with causal agent,
Mycobacterium tuberculosis. Within the large pool of persons with
latent TB infection (LTBI) there is a ,5% lifetime risk of
developing active TB disease. TB disease risk is influenced by
inherited and acquired susceptibility factors. HIV/AIDS has long
been appreciated as a major acquired risk factor, with relative risk
estimated between 20 and 37 depending on the local state of the
HIV epidemic [2]. Diabetes and exposure to cigarette smoke have
more recently been identified as acquired risk factors for TB [3,4].
While the TB risk conferred by diabetes is lower than HIV/AIDS,
its high prevalence makes it comparable to HIV/AIDS in terms of
global population-attributable TB risk [5].
In addition to increasing the risk for developing active TB there
is evidence that diabetes is also associated with greater severity of
TB disease. It has been linked to higher mortality, delayed sputum
conversion, increased radiographic extent of disease and greater
risk of recurrent TB after treatment [6]. While published evidence
has generally supported the hypothesis that diabetes increases TB
severity there have been inconsistencies in identifying certain
associations, including delayed sputum conversion and increased
risk for multi-drug resistant (MDR) TB, and differences in the
estimated impact of diabetes on TB mortality. In many studies of
TB and diabetes, data were not adjusted for potentially
confounding variables and study populations tended to be small.
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To expand the base of knowledge on this topic we made use of
data collected prospectively in a Natural History Study ongoing at
the International TB Research Center and the National Masan
Tuberculosis Hospital in the Republic of Korea. We aimed to
evaluate the impact of diabetes on the clinical presentation,
treatment response and outcomes of pulmonary TB. Our primary
goal was to test the hypothesis that co-morbid diabetes increases
the risk for adverse TB outcomes. Secondary goals included
analyzing the combined effects of diabetes and smoking, and
testing the impact of diabetes on TB outcomes specifically in the
Korean population. There is potential for geographic and ethnic
differences in the effects of diabetes on TB disease manifestations
and outcomes that have not been adequately investigated. Such
differences could arise due the relative virulence of locally
prevalent M. tuberculosis clades, along with potential differences in
host genetic susceptibility to TB and/or differences in the
mechanisms and manifestations of type 2 diabetes in distinct
populations [7,8]. The Korean population is ethnically and
genetically homogeneous, and nearly all M. tuberculosis isolates in
Korea belong to the Beijing clade [9].
Materials and Methods
Study Design and Population
Participants were recruited from patients presenting to the
National Masan Tuberculosis Hospital (NMTH) for the manage-
ment of active TB disease. Subjects with a first-ever diagnosis of
TB were assigned to cohort A while those previously treated for
TB were assigned to cohort B. Inclusion criteria were males and
females $20 years of age with symptoms compatible with active
TB and a positive sputum smear for acid-fast bacilli (AFB). An
additional inclusion criterion for cohort A was ,30 days of
antibiotic treatment for TB prior to enrollment. Pregnancy and
HIV were exclusion criteria. Subjects with positive sputum smears
at the time of enrollment but whose cultures subsequently grew
only non-tuberculous mycobacteria (2/659) where withdrawn
from the study. Subjects remained as inpatients at NMTH for an
average of 165 days, according to usual clinical practice at that
institution. Subjects discharged from the inpatient service at
NMTH were subsequently followed in the NMTH outpatient
clinic. Whenever possible, information on the outcomes for those
no longer seen at NMTH was obtained from the subjects or their
families as permitted by human studies protocols.
Procedures and Investigations
Demographic data and clinical history were recorded by study
nurses and routine laboratory data were collected from the
NMTH medical record. The Natural History Study was not
originally designed to focus on the influence of diabetes on TB
outcomes but diabetic patients within cohorts could be reliably
identified, allowing comparison to those without diabetes. Subjects
were scored as diabetic if they described a history of this condition
at the time of enrollment, if they were taking anti-diabetic
medications prior to hospital admission, or if they had random
blood glucose $200 mg/dL on two separate days in hospital.
Chest X-rays were read by hospital radiologists and scored in
blinded fashion according to a predetermined protocol used by the
Korean Centers for Disease Control [10]. Radiographs were
scored as showing minimal, moderately advanced, or far advanced
TB, or having no TB disease evident. The presence or absence of
cavitation and nodules was recorded, as were all lung lobes
involved with disease.
Sputum for mycobacterial smear and culture was collected at
months 0 1, 2, 4, and 6 of treatment according to usual clinical
practice at NMTH and shared with the study staff. These tests
were performed by standard methods in the laboratory of the
International Tuberculosis Research Center, located adjacent to
NMTH. Sputum was cultured on Ogawa solid media and in an
MB/BacT liquid growth system. Drug sensitivity testing was
performed on all positive cultures. Positive Ziehl-Neelsen stained
sputum smears and solid media cultures were scored on a scale
ranging from scanty to 4+. All subjects were inpatients at NMTH
for at least the first 4 months of treatment and received directly
observed therapy. Subjects with drug resistant TB remained in
hospital for up to 7 months and, following discharge, were
readmitted to the inpatient service if follow-up sputum smears
were positive. Subjects having positive smear or culture at 6
months prompted a continuation of monthly sputum testing out to
12 months. Subjects positive beyond 12 months were monitored
with cultures done at the discretion of the attending physicians.
Treatment regimens in cohort B were individually tailored based
on individual subject TB history and any available previous
antimicrobial sensitivity testing data.
Statistical Methods
Two-group comparisons of demographics at enrollment (cohort
A vs. B) were made using chi-square tests for categorical measures
and Student’s t-tests for comparison of means. Unadjusted rates of
diabetes were compared among cohorts using Fisher’s exact tests.
Odds Ratios (OR) for risk of diabetes were estimated and tested
using logistic regression. Patients in cohorts A and B were matched
using propensity score matching. The propensity (of being in
cohort B) was estimated using age, gender, levels of drinking and
smoking, education and occupation. Matching was carried out for
all patients and separately with in age groups (age ,50 and age
$50). Estimates and tests of OR for the matched populations were
generated using Generalized Estimating Equation logistic regres-
sion clustering on matched patients. Rank sum tests compared
smear and culture scores; adjusted comparisons were made using
linear regression. Time to clearance of sputum smear and culture
was limited to cohort A. Unadjusted rates of time to clearance
were estimated using Kaplan-Meier curves and adjusted time to
clearance was modeled and tested using Cox regression. Rates of
MDR-TB were compared using logistic regression models.
Unadjusted mortality was estimated using Kaplan-Meier estima-
tion. Cox regression models estimated unadjusted and adjusted
hazard ratios. The association of diabetes and age was examined
using lowess curves [11]. All analyses were carried out using Stata
12 (StataCorp, College Station, TX).
Ethics
Individual participants in this study gave written informed
consent under protocols approved by the Institutional Review
Boards of the National Masan Tuberculosis Hospital (Republic of
Korea) and the National Institute of Allergy and Infectious
Diseases, National Institutes of Health (United States). Investiga-
tors from the University of Massachusetts Medical School were
subsequently added to the National Masan Tuberculosis Hospital
and National Institute of Allergy and Infectious Diseases protocols,
but accessed only de-identified patient data.
Results
Cohort Description
Subjects were offered enrollment in the Natural History Study
on presentation to NMTH for management of TB and stratified
into those with first-ever TB (cohort A) or retreatment of TB
(cohort B). Bacterial genotyping data on isolates obtained prior to
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enrollment were not available to determine whether individual
subjects in cohort B represented treatment failure with persistently
positive cultures, relapse of prior infection with the same strain
after culture conversion or exogenous reinfection with a different
M. tuberculosis strain. The rate of exogenous reinfection in the
Korean population has not been reported. Using an algorithm
based on the incidence of TB in a general population proposed
and tested by Wang et al. [12], reinfection in Korea can be
estimated in the range of 20–30%. Thus, most subjects in cohort B
represented failure to clear initial infection or relapse with the
same organism after clinical cure. Within the 657 total active TB
cases, subjects in cohort B were younger, smoked less and had
higher education than those in cohort A (Table 1).
Rates of diabetes were compared between cohort A (23.3%) and
cohort B (25.2%), overall and within age groups ,50 and $50
years (Table 2). While the multivariable adjusted OR was 1.15
(p = 0.517), the matched patient population showed an estimated
increased risk for diabetes in cohort B, OR=1.47 (p= 0.089). We
noted that the association of diabetes and age was not linear (Fig. 1)
so the risk of diabetes by cohort was examined within age groups
(age ,50 and age $50). Both matched and unmatched analyses
indicated that the risk of diabetes in cohort B vs. cohort A differed
by age group. There was no significant difference in the risk
between these two cohorts for age,50, but there was an increased
risk for diabetes in cohort B vs. cohort A for age $50 (OR=3.05
unmatched, 2.22 matched). The multivariable model of diabetes
risk included an interaction term of cohort and age group, testing
the premise that ORage,50 =ORage$50 and estimated a significant
difference between the odds ratios (p = 0.002), where ORage,50
represents the risk of diabetes in cohort B vs. A within age
group,50. This result was consistent with prior studies that
demonstrated an increased risk for recurrent TB in diabetic vs.
non-diabetic TB patients although in our population this was
restricted to the older age group [6].
Characteristics on Presentation
At enrollment, radiographic measures and culture scores were
compared (Table 3). Chest X-rays were read by radiologists
blinded to patient status and graded according to a standardized
scoring scheme. Comparing subjects with or without diabetes,
there were no significant differences in rates of bilateral disease,
cavitation or mid-lower lung zone opacities. There was, however,
a significant difference in radiographic severity scores with non-
diabetic subjects more likely than diabetic subjects to have
radiographically minimal disease.
There were no significant differences in sputum smear scores or
culture scores, comparing diabetic with non-diabetic subjects.
MDR-TB was identified at the time of enrollment in 16 of 192
(8.3%) of subjects in cohort A for whom data were available and
213/372 (57.3%) of subjects in cohort B. There was no significant
difference in rates of MDR-TB comparing all diabetic to all non-
diabetic subjects (Table 3), or when diabetic and non-diabetic
subjects within cohort A or cohort B were compared individually
(not shown). The high rate of MDR-TB in cohort B reflects that
fact that these were retreatment cases.
Response to Antimicrobial Treatment
Subjects in cohort A began treatment with isoniazid, rifampin,
pyrazinamide and ethambutol (HRZE) with the intention to
complete a 6–9 month standard short-course regimen. Any form
of treatment for TB disease for .30 days prior to enrollment was
an exclusion criterion for subjects in cohort A, making this cohort
suitable for evaluation of sputum smear and culture conversion
rates. Survival analysis was used to compare the rate of culture
conversion after 2, 4 and 6 months of treatment. No statistically
significant difference was observed between diabetic and non-
Table 1. Demographic comparison of cohorts.*
Cohort A Cohort B A vs. B
n (%)** n (%)** p-value
All subjects 220 437
Female 36 (16.4) 70 (16.0) 0.91
Age 46.6615.0 43.5613.2 0.005
Smoking status 213 413 ,0.001
& Non-smoker 47 (22.1) 98 (23.7)
& ,1 pack per week 30 (14.1) 122 (29.5)
& 1 pack per day 76 (35.7) 120 (29.1)
& .1 pack per day 60 (30.8) 73 (17.7)
Drinking 220 437 0.139
& None 80 (33.4) 192 (43.9)
& #4 per week 57 (25.9) 115 (26.3)
& 1 per day 15 (6.8) 29 (6.6)
& .1 per day 68 (30.9) 101 (23.1)
Education 206 421 0.007
& Elem. School 47 (22.8) 61 (14.5)
& Middle School 40 (19.4) 115 (27.3)
& High School 97 (47.1) 179 (52.5)
& Univ/Prof 22 (10.7) 66 (15.7)
Occupation 219 435 0.024
& Prof/office/health 16 (7.3) 54 (12.4)
& Service sector 45 (20.6) 120 (27.6)
& Laborer 81 (37.0) 120 (27.6)
& Other 37 (16.9) 62 (14.3)
& None 40 (18.3) 79 (18.2)
MDR-TB 16 (8.3) 213 (40.6) ,0.01
*Cohort A, first ever TB diagnosis; cohort B, retreatment for TB.
**Includes only subjects where data on smoking, drinking, education and
occupation were available.
doi:10.1371/journal.pone.0058044.t001
Figure 1. Non-linear association of diabetes and age. Lowess
smoothing curve [10] fit to diabetes prevalence vs. age. A spline fit
model (knot at age = 50) is significantly different from a linear fit
(p,0.001).
doi:10.1371/journal.pone.0058044.g001
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diabetic subjects in cohort A (Table 4). Time to culture conversion
was not evaluated in cohort B since many subjects had received
antimicrobial treatment for variable intervals longer than 30 days
before admission to NMTH and many were already on treatment
and the time of enrollment in this study.
Mortality Rates
Unadjusted survival was 87% in diabetics vs. 94% in non-
diabetics during the first year after enrollment and TB treatment
at NMTH. The adjusted hazard ratio (HR) for all-cause mortality
in diabetic subjects compared with non-diabetic subjects, adjusted
for cohort, age, gender and smoking was 2.18 (95% CI: 1.10, 4.34;
Table 5). For TB-related deaths, the HR=1.98 (95% CI: 0.90,
4.35; Table 6). Adjusting for MDR-TB in the all-cause or TB-
related mortality models did not change the results appreciably,
with HR=2.40 (95% CI: 1.19, 4.2) for all-cause mortality and
HR=2.06 (95% CI: 0.94, 4.54) for TB-related deaths. This was
unsurprising since drug resistance was highly correlated with
cohort B that is included in the adjustment. MDR-TB status was
missing in approximately 14% of the patients, so data presented in
Tables 5 and 6 do not include the adjustment for MDR-TB. TB-
related deaths in this study were attributable to respiratory failure,
hemoptysis and to extrapulmonary TB (the latter reflecting only 2
of 49 TB-related deaths). Hemoptysis was the cause of death in the
Table 2. Rates of diabetes overall and by age group and cohort.
Unadjusted diabetes rate (%) p-value Odds Ratio* [95% CI]
Cohort A Cohort B Cohort B vs. Cohort A
Overall 52/220 (23.6) 110/437 (25.2) 0.517 1.15 [.75, 1.78]
& Age ,50 34/140 (24.3) 53/302 (17.6) 0.269 0.75 [0.45,1.25]
& Age $50 18/80 (22.5) 57/135 (42.2) 0.003 3.05 [1.46, 6.36]
Matched Cohorts** 46/197 (23.4) 61/197 (31.0) 0.089 1.47 [0.95, 2.29]
& Matched, age ,50 33/135 (24.4) 29/135 (21.5) 0.56 0.85 [0.48, 1.49]
& Matched, age $50 13/62 (20.9) 23/62 (37.1) 0.049 2.22 [1.00, 4.92]
*Adjusted for age, gender, smoking, drinking, education, occupation.
**Estimates and p-values based on generalized estimating equation regression.
doi:10.1371/journal.pone.0058044.t002
Table 3. Subject characteristics on enrollment.
Non-Diabetic Diabetic p-value
n (%) n (%) Unadjusted Adjusted*
Radiographic severity 495 162 0.04 0.03
Minimal 18 (3.6) 1 (0.6)
Moderate 207 (41.8) 80 (49.4)
Advanced 270 (54.6) 81 (50.0)
Mid-lower opacities** 388 (78.4) 138 (85.2) 0.07 0.23
Bilateral lung disease 414 (83.7) 137 (84.5) 0.90 0.78
Cavitary lung disease 304/419 (73.5) 100/134 (74.6) 0.82 0.91
Smear Score 495 162 0.52 0.38
2 109 (22.0) 30 (18.5)
+ 270 (54.6) 93 (57.4)
++ 93 (18.8) 32 (19.8)
+++ 23 (4.7) 7 (4.3)
++++ 0 0
Culture Score 495 158 0.92 0.90
2 120 (24.2) 33 (20.9)
+ 136 (27.5) 45 (28.5)
++ 76 (15.4) 38 (24.1)
+++ 160 (32.3) 42 (26.6)
++++ 3 (0.6) 0
MDR-TB 174 (40.8) 55 (40.2) 0.92 0.94
*Adjusted for cohort, age, gender, smoking.
**Opacities in the right middle lobe, right lower lobe, or left lower lobe.
doi:10.1371/journal.pone.0058044.t003
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first year for 5 of 11 (46%) subjects with diabetes vs. 4 of 18 (22%)
non-diabetic subjects, but this did not reach statistical significance.
Figure 2 illustrates the unadjusted Kaplan-Meier estimates for all
deaths, stratified by the presence or absence of diabetes and by age
group. The survival difference between diabetic and non-diabetic
subjects occurred mainly within the first 6 months of enrollment
and treatment, after which the Kaplan-Meier curves were
relatively parallel. The impact of diabetes on all-cause mortality
was estimated to be greater in subjects ,50 years of age
(HR=3.91 [95% CI: 1.54, 9.98]) than subjects $50 years old
(HR=1.12 [95% CI: 0.39, 3.18]). The test of interaction of
diabetes and age resulted in p= 0.09 for all deaths. A similar
interaction was estimated for TB-related deaths, with the impact of
diabetes greater in subjects ,50 years HR=3.7 compared to the
impact subjects .50 years, HR=0.92 (p = 0.10; Fig. S1).
In the adjusted models there was an estimated increase in risk of
mortality for smokers vs. nonsmokers for all causes of death and
for TB-related death. Of note, only 20% of diabetic subjects were
self-described non-smokers while a majority (54%) admitted to
smoking $1 pack of cigarettes daily prior to enrollment. No
patients were permitted to smoke after admission to NMTH.
Interaction of diabetes and smoking was not significant (p.0.50 in
all cases). The hazard for diabetics who also smoke cigarettes could
therefore be estimated by combining the two risks (estimated risk
in a diabetic, $ one pack smoker vs. non-diabetic, non-smoker).
For all deaths, HR=4.25 [95% CI: 1.06, 17.08] and for TB-
related deaths: 5.78 [95% CI: 1.09, 30.56].
Discussion
Despite its advanced economy, the Republic of Korea has
relatively high TB incidence (97/100,000 in 2006) [13]. The
prevalence of diabetes is also high in Korea, estimated at 9.1% in
2005 as compared to ,1% in 1970 [14]. It is therefore important
to understand the impact that diabetes has on the manifestations
and outcomes of TB disease in the Korean population, and its
relationship to similar data from other populations. Our investi-
gation made use of a large, prospectively recruited cohort of TB
patients at NMTH. The 25% prevalence of diabetes in this TB
cohort is in line with the prevalence of diabetes in the general
Korean population and an approximately 3-fold increased TB risk
for people with diabetes reported in previous studies [5]. Results in
the current study were consistent with an adverse impact of
diabetes on TB disease severity, reflected by increased mortality at
one year.
A recent meta-analysis of evidence pertaining to the impact of
diabetes on TB outcomes identified four studies where mortality
data were adjusted for age and certain other potential confounders
[6]. These include a retrospective review by Fielder et al. [15] of
174 subjects with TB reported to the Baltimore City Health
Department between 1993 and 1998, that calculated an adjusted
OR for death in the 22 diabetic subjects of 3.8 (95% CI:1.4, 10.3).
The median time to death after starting TB treatment was 32 days
and the majority of deaths were due to causes other than TB.
Oursler et al. [16] also retrospectively evaluated 139 subjects with
pulmonary TB reported to the Baltimore City Health Department
between 1994 and 1996. Eighteen subjects (14%) had diabetes
with adjusted HR for mortality of 6.7 (95% CI:1.6, 29.3).
Reflecting that this was a subset of the same population reported
by Fielder, the overall mortality was 21% with a median time to
death of 39 days. The third published study reporting adjusted
mortality data in TB patients was conducted retrospectively in
cases of culture-confirmed disease in Montgomery County, Prince
George’s county and Baltimore City in Maryland, USA [17].
Overall mortality for the 217 subjects was 9%. Mortality in the 42
subjects (14%) with diabetes was higher than non-diabetic subjects
(OR=6.5; 95% CI: 1.11, 38.20). Drug-resistant bacilli were found
on initial culture in a similar proportion of diabetic and non-
diabetic subjects (14.1% and 15.1%, respectively), none of the 26
deaths occurred in subjects with MDR-TB and there was no
acquired drug resistance was recorded. Finally, Wang et al. [18]
retrospectively reviewed 271 culture-positive pulmonary TB
patients at the Kaohsiung Municipal Hsiao-Kang Hospital in
Taiwan between 2003 and 2006, of whom 74 (34%) were diabetic.
All-cause mortality at one year in the diabetic group was 12.2%
compared to 4.2% in non-diabetic subjects (OR=7.6 adjusted for
age and gender; 95% CI: 1.976, 29.083). The mean age of diabetic
and non-diabetic subjects in that study (60.8 and 59.1) was nearly
two decades older than our cohort, and they found that older age
was an independent predictive factor for unfavorable outcomes.
Our findings in 557 prospectively recruited Koreans with TB
disease were generally consistent with the outcome studies cited
above, albeit with some qualitative and quantitative differences
that may reflect the geographic location and demographics of the
populations studied. The reports of Fielder, Oursler, and Dooley
used data collected in Baltimore or adjacent counties in Maryland
and those of Fielder and Oursler appear to have analyzed a largely
overlapping set of records. All three studies reported strikingly high
early mortality. The impact of diabetes on mortality risk in our
cohort was quantitatively more comparable to summary RR 1.89
for all 23 studies reviewed by Baker et al. [6], most being
unadjusted. These differences in overall mortality for our study vs.
Table 4. Sputum culture conversion in cohort A.*
2 Months 4 Months 6 Months
% Negative Culture
& Diabetic (n = 44) 70.8% 90.3% 92.7%
& Non-Diabetic (n = 137) 70.8% 92.0% 97.3%
*Rates based on survival analysis; unadjusted p-value = 0.92; adjusted p-
value = 0.98.
doi:10.1371/journal.pone.0058044.t004
Figure 2. Survival estimates. Unadjusted Kaplan-Meier survival
curve for all causes of death in diabetic subjects (red lines) and non-
diabetic subjects (blue lines) grouped by age $50 (dashed lines) or age
,50 (solid lines). Separate curves by age (dashed vs. solid) and diabetes
(red vs. blue) illustrate the interaction of diabetes and age on survival.
For age ,50 the separation between diabetic vs. non-diabetic subjects
is larger than for age $50.
doi:10.1371/journal.pone.0058044.g002
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the four studies with adjusted data may reflect the high proportion
of subjects co-infected with HIV (24%) in the cohorts of Fielder
and Oursler, and the older age of the population reported by
Wang. In a separate report of 157 TB cases collected at the
Kaohsiung Municipal Hsiao-Kang Hospital in Taiwan between
2003 and 2006, Wang et al. [19] focused on the impact of age on
outcomes. All-cause mortality in subjects $60 years old (median
age 74) was 26.5% in contrast to 4.1% for younger patients
(median age 46) despite comparable frequencies of diabetes in the
two groups (32.5% and 29.7%, respectively). Deaths in diabetic vs.
non-diabetic subjects within the two age groups were not described
in that report. In contrast to the studies from Taiwan and
Baltimore, relative youth had no evident protective effect for all-
cause mortality in our cohort where 21.3% of diabetic subjects
$50 and 17.2% of diabetic subjects ,50 died within one year of
enrollment.
Our study also differed from those of Fielder, Oursler, Dooley
and Wang by considering the impact of smoking on TB mortality.
This question was recently investigated in a 14-year prospective
cohort of 1,294,504 Koreans aged 30–95 who participated in a
biennial National Health Insurance Corporation medical evalua-
tion [4]. Smoking was associated with increased mortality from TB
in men and women, with similar risks for current and former
smokers and no indication of increasing risk based on the number
of cigarettes smoked daily. For male current smokers vs. non-
smokers in that study, HR=1.58 (95% CI: 1.27, 1.97). Smoking
and diabetes are highly prevalent conditions that increase the risk
of developing active TB and the risk of adverse outcomes from TB
disease [4,5]. We confirmed the lack of interaction between
smoking and diabetes in our cohort and found that the
combination of smoking and diabetes significantly increased the
hazard of death from all causes and death attributable to TB
disease in comparison to non-diabetic, non-smokers. This adverse
impact of smoking history was observed despite the fact that
subjects were not permitted to smoke while inpatients at NMTH.
Our investigation of TB outcomes had several limitations. The
study population was biased for greater TB severity with a large
number of retreatment cases (cohort B). This could reduce any
detectable impact of diabetes on outcomes. Arguing against that,
we found a similar impact of diabetes on mortality in cohorts A
and B. Our analysis of mortality was hampered by the fact that the
cause of death information was unavailable for one quarter of the
subjects who expired. The variable initiation of TB treatment
prior to enrollment in cohort B made it impossible to reliably track
time to sputum conversion in that group. Finally, the original
design of the Natural History Study from which data were
extracted was not focused on diabetes. While subjects could be
identified as having diabetes or not, the duration and severity
diabetes in individual subjects was unknown. This is a major
limitation for many studies of this topic. Limited clinical
Table 5. Impact of diabetes and smoking on all cause one-year mortality.*
All Deaths Unadjusted** All Deaths Adjusted**
Hazard Ratio [95% CI] p-value Hazard Ratio [95% CI] p-value
Diabetic Non-diabetic 1***
Diabetic 2.41 [1.27, 4.59] 0.007 2.18 [1.10, 4.34] 0.026
Smoker Nonsmoker 1 1
,1 pack 0.83 [0.34, 1.99] 0.67 1.46 [0.46, 4.66] 0.520
$1 pack 0.59 [0.27, 1.31] 0.20 1.95 [0.59, 6.46] 0.273
Cohort A 1 1
B 2.96 [1.24, 7.07] 0.015 3.58 [1.36, 9.41] 0.010
Age Years 1.03 [0.99, 1.07] 0.122 1.04 [1.00, 1.09] 0.067
Age $50 ,50 1 1
$50 0.83 [0.27, 2.51] 0.74 0.60 [0.19, 1.88] 0.384
Drinker No 1 1
Yes 0.32 [0.16, 0.64] 0.001 0.36 [0.16, 0.78] 0.009
Sex Male 1 1
Female 1.57 [0.72, 3.43] 0.257 2.19 [0.72, 6.67] 0.166
Education Elem. 1 1
Middle 0.75 [0.29, 1.94] 0.553 0.67 [0.23, 1.96] 0.467
High Sch 0.68 [0.28, 1.62] 0.381 0.79 [0.29, 2.14] 0.637
Univ/Prof 1.03 [0.36, 2.96] 0.963 1.30 [0.39, 4.31] 0.670
Combined effects
Diabetic smoker ,1 pack 3.19 [0.82, 12.38] 0.09
$1 pack 4.25 [1.06, 17.08] 0.04
*Smoking included a ‘missing’ group (not shown) in order to not lose data (5% missing); Age as continuous (linear) and an age indicator (,50 vs. $50) were included
together for unadjusted age association. Combined Diabetes and smoker are additive main effects (not an interaction); comparison of diabetic smoker vs. non-diabetic
non-smoker.
**The column All Deaths Unadjusted shows estimated unadjusted associations of each factor with death. The column All Deaths Adjusted shows estimated adjusted
associations from a single model using all the factors in the table (each factor is adjusted for all other factors in that table). The combined effect at the bottom is a
combination of coefficients for diabetes and smoking from the adjusted model.
***Reference value.
doi:10.1371/journal.pone.0058044.t005
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information and results from the mouse model suggest that like
most other complications of diabetes, TB susceptibility results from
a cumulative impact of chronic hyperglycemia [20–23]. While the
possible correlation of diabetes severity with TB outcomes has not
been directly tested, Baker et al. [24] recently reported that TB
disease risk is increases as the number of diabetes-related
complication increases.
Our study adds to a growing body of evidence that diabetes
mellitus not only increases the risk of developing active TB but also
increases the severity of TB disease, reflected by higher risk of
recurrent TB and death. We further show that diabetes and
smoking are independent risks for adverse outcomes with TB
disease that in combination significantly increase the hazard of
TB-related death. This is concerning in view of the rising rates of
diabetes and tobacco use in the emerging economies of Asia where
TB is already prevalent. Also concerning in our results was the
finding that diabetes was associated with increased mortality in
subjects ,50 years old. Evidence that diabetes and smoking
contribute significantly to TB disease risk and severity raises the
question whether current public health and TB control practices
adequately address the problem. Presently, diabetic patients with
drug sensitive TB are treated with short course HRZE. The
increased risk of relapse in this population suggests the need to test
the efficacy of prolonging the consolidation phase of treatment in
patients with diabetes. Similarly, the increased risk of death during
TB treatment might be addressed by intensifying management
and observation in patients with diabetes, particularly those who
smoke. The combined impact of diabetes and smoking on TB
disease risk and mortality may provide a rationale to treat latent
TB infection in those at risk, which is not current clinical practice
in low and middle income countries [25]. An interventional trial of
LTBI treatment in diabetics would be necessary to confirm safety
and efficacy in that population.
Supporting Information
Figure S1 Adjusted Diabetes*age interaction model.
Estimated survival curves based on adjusted Cox regression
models for all-cause mortality (A) and TB-related mortality (B) in
diabetic subjects (red lines) and non-diabetic subjects (blue lines)
stratified by age $50 (dashed lines) or age ,50 (solid lines). The
impact of diabetes (red vs. blue lines) is greater in subjects age ,50
years old.
(PDF)
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Table 6. Impact of diabetes and smoking on one-year mortality attributable to TB.*
TB Deaths Unadjusted** TB Deaths Adjusted**
Hazard Ratio [95% CI] p-value Hazard Ratio [95% CI] p-value
Diabetic Non-diabetic 1*** 1
Diabetic 2.02 [0.95, 4.27] 0.067 1.98 [0.90, 4.35] 0.091
Smoker Nonsmoker 1 1
,1 pack 1.10 [0.38, 3.18] 0.855 2.10 [0.53, 8.30] 0.29
$1 pack 0.79 [0.30, 2.11] 0.395 2.93 [0.70, 12.28] 0.14
Cohort A 1 1
B 3.45 [1.20, 9.92] 0.022 3.48 [1.18, 10.27] 0.024
Age Years 1.02 [0.98, 1.07] 0.309 1.04 [0.99, 1.09] 0.125
Age $50 ,50 1 1
$50 0.86 [0.24, 3.06] 0.813 0.60 [0.17, 2.16] 0.431
Drinker No 1 1
Yes 0.31 [0.14, 0.69] 0.004 0.32 [0.13, 0.77] 0.431
Sex Male 1 1
Female 1.53 [0.62, 3.75] 0.355 3.03 [0.87, 10.51] 0.081
Education Elem. 1 1
Middle 0.89 [0.31, 2.57] 0.830 0.75 [0.23, 2.45] 0.627
High Sch 0.71 [0.26, 1.92] 0.501 0.74 [0.24, 2.30] 0.599
Univ/Prof 0.91 [0.26, 3.22] 0.880 1.05 [0.25, 4.36] 0.943
Combined effects
Diabetic smoker ,1 pack 4.14 [0.83, 20.71] 0.08
$1 pack 5.78 [1.09, 30.56] 0.04
*Smoking included a ‘missing’ group (not shown) in order to not lose data (5% missing); Age as continuous (linear) and an age indicator (,50 vs. $50) were included
together for unadjusted age association. Combined Diabetes and smoker are additive main effects (not an interaction); comparison of diabetic smoker vs. non-diabetic
non-smoker.
**The column TB Deaths Unadjusted shows estimated unadjusted associations of each factor with death. The column TB Deaths Adjusted shows estimated adjusted
associations from a single model using all the factors in the table (each factor is adjusted for all other factors in that table). The combined effect at the bottom is a
combination of coefficients for diabetes and smoking from the adjusted model.
***Reference value.
doi:10.1371/journal.pone.0058044.t006
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